#antivenom-supply-chain

Rural snakebite victims in low- and middle-income countries die from envenoming that existing antivenom could treat, because effective products are priced out of reach, commercially withdrawn, absent from remote clinics, or arrived too late — an access, market, and logistics fail

Stabilise antivenom supply with guaranteed-volume pooled procurement, donor/government subsidy, WHO prequalification, and regional manufacturing — so effective, region-matched antivenom stays commercially viable and reaches clinics affordably.

Produce and distribute lyophilised (freeze-dried) antivenom with a multi-year ambient shelf life so it can be stocked at rural health posts and remote clinics where refrigeration is unreliable or absent.

Systematically test which existing polyvalent antivenoms already neutralize orphan-species venoms via antivenomics and preclinical assays, then pursue label extensions — expanding effective coverage without developing new products.

A counter-example to the FAV-Afrique collapse: effective, region-matched African antivenom developed and sustained through public-academic partnership rather than a purely commercial market. EchiTAb-G (ovine, monospecif…

FAV-Afrique was a polyvalent antivenom covering ~10 snake species across sub-Saharan Africa, considered safe and effective. Sanofi Pasteur halted production in 2010 (last batch made 2014, expired June 2016) after sales…

PANAF-Premium is a freeze-dried polyvalent antivenom requiring no refrigeration, with a manufacturer-stated ambient shelf life of approximately 4 years. A preclinical study evaluated PANAF and a 'Panafrican' ICP product…

Rather than develop a new product, researchers tested whether an existing polyvalent antivenom (PANAF-Premium, Premium Serums & Vaccines) already neutralizes the venoms of medically important sub-Saharan African snakes…